German Inclisiran Network: Retrospective Registry of Patients Being Treated With the siRNA Inclisiran in Germany

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The German Inclisiran Network is a registry of patients with hypercholesterinemia on treatment with the siRNA inclisiran in Germany

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• patients with elevated LDL-C levels (hypercholesterolemia) on stable lipid-lowering drugs for at least one month prior to the application of the siRNA Inclisiran

• patients 18 years and older

Locations
Other Locations
Germany
Jena University Hospital
RECRUITING
Jena
Contact Information
Primary
Oliver Weingaertner, MD
oliver.weingaertner@med.uni-jena.de
+4936419324521
Backup
Martin Foerster, PhD
martin.foerster@med.uni-jena.de
+4936419325818
Time Frame
Start Date: 2020-12-11
Estimated Completion Date: 2025-12-11
Participants
Target number of participants: 500
Treatments
Patients with elevated LDL-cholesterol (hypercholesterolemia)
Application of si RNA Inclisiran to reduce serum LDL-cholesterol levels.
Related Therapeutic Areas
High Cholesterol
Sponsors
Collaborators: Universitätsklinikum Leipzig, Charite University, Berlin, Germany, Technische Universität Dresden, Deutsches Herzzentrum Muenchen, Ruhr University of Bochum, Universitätsmedizin Mannheim, LMU Klinikum, University of Rostock
Leads: Jena University Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy - CHOLINET (CHOLesterol Italian Inclisiran NETwork)

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy - CHOLINET (CHOLesterol Italian Inclisiran NETwork)

Enrollment Status: Recruiting
Publish Date: March 19, 2024
Intervention Type: Drug

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol

Enrollment Status: Recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Phase: Phase 3

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol

Enrollment Status: Recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Phase: Phase 3
View All